Table 3 Summary of results of infliximab therapy in patients with refractory inflammatory myopathies
PatientDiagnosisImproved ⩾20%Worsened ⩾30%Adverse eventsClinical outcome*CK before/afterMMT before/afterFI before/after
1PMDGA, PGA, HAQ, CK, exm: arthritisNoNoImproved1.8/1.357/6123/31
2PMDGA, HAQ, exm: arthritisexm: skin, dysphagia, myalgiaNoImproved1.9/3.966/7349/54
3PMHAQDGA, CK, exm: myalgiaAbdominal pain, fatigueWorse4/16.876/7756/58
4PMNoDGA, CK, exm: arthralgia, myalgiaAbdominal pain, fatigueWorse4.4/8.165/6434/27
5PMDropped out after two infusionsNoCoughDropped out4.3/–54/–15/–
6DMDGA, HAQCKAbdominal painUnchanged1.8/2.748/5642/42
7DMDropped outNoToxicodermiaDropped out47/–63/–40/–
8DMDropped outNoDiscovered malignancyDropped out11/–68/–56/–
9DMDropped outCKIncreased general symptoms and muscle fatigueDropped out88/–55/–
10IBMDGA, PGA, HAQexm: GI, feverNoImproved3.3/2.761/5632/33
11IBMNoexm: dysphagiaNoUnchanged2.5/2.349/5725/33
12IBMDGANoSkin, fatigueUnchanged4.6/3.859/6534/35
  • *Clinical change according to the IMACS definition,22 .

  • CK, creatine kinase (men <3.3 μkat/litre, women <2.5 μkat/litre); DGA, doctor’s global assessments of disease activity; exm, extra muscular symptoms; FI, functional index (64 = maximum muscle function); GI, gastrointestinal symptom; HAQ, health assessment questionnaire; MMT, manual muscle test (8 muscle group, scoring 0–10, 80 = maximum strength); PGA, patient’s global assessments of disease activity.